Biocryst hopes to contribute antiviral to bird-flu fight

10/20/2005 | CNNMoney

Biocryst Pharmaceuticals expects to complete Phase I testing of its Peramivir antiviral by next March, and while the company expects to complete Phases II and III tests, the government may intervene to contribute to U.S. stockpiles of drugs to combat a possible flu outbreak. Pre-clinical testing in mice showed the drug could cure the avian flu virus without side effects and NIH is providing funding for the trials. The government has not offered Biocryst a contract at this time, however.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL